CO2022011684A2 - Células t con car de bcma con actividades mejoradas - Google Patents
Células t con car de bcma con actividades mejoradasInfo
- Publication number
- CO2022011684A2 CO2022011684A2 CONC2022/0011684A CO2022011684A CO2022011684A2 CO 2022011684 A2 CO2022011684 A2 CO 2022011684A2 CO 2022011684 A CO2022011684 A CO 2022011684A CO 2022011684 A2 CO2022011684 A2 CO 2022011684A2
- Authority
- CO
- Colombia
- Prior art keywords
- immune cells
- cells
- genetically engineered
- engineered immune
- bcma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980914P | 2020-02-24 | 2020-02-24 | |
| US202063020713P | 2020-05-06 | 2020-05-06 | |
| US202063053409P | 2020-07-17 | 2020-07-17 | |
| US202063092681P | 2020-10-16 | 2020-10-16 | |
| PCT/US2021/019362 WO2021173630A1 (en) | 2020-02-24 | 2021-02-24 | Bcma car-t cells with enhanced activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022011684A2 true CO2022011684A2 (es) | 2022-08-30 |
Family
ID=75108802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0011684A CO2022011684A2 (es) | 2020-02-24 | 2022-08-19 | Células t con car de bcma con actividades mejoradas |
Country Status (15)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230138428A1 (en) * | 2020-02-25 | 2023-05-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| KR20230171994A (ko) | 2021-04-16 | 2023-12-21 | 셀진 코포레이션 | 선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법 |
| WO2023081735A1 (en) | 2021-11-03 | 2023-05-11 | Celgene Corporation | Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma |
| KR20240137075A (ko) | 2022-01-28 | 2024-09-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 조성물의 제조 방법 |
| EP4499680A1 (en) * | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| US20250295771A1 (en) | 2022-05-11 | 2025-09-25 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
| CN117126856A (zh) * | 2022-05-20 | 2023-11-28 | 上海雅科生物科技有限公司 | 以bcma胞外结构域为标记的基因、多肽、重组表达载体、基因工程化细胞及其应用 |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| CN119836438A (zh) * | 2022-09-19 | 2025-04-15 | 艾洛基治疗公司 | B-细胞成熟抗原(bcma)抗独特型抗体 |
| US20260166082A1 (en) | 2022-11-02 | 2026-06-18 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| WO2024168192A1 (en) | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
| CN121532650A (zh) | 2023-06-20 | 2026-02-13 | 艾洛基治疗公司 | 工程化的细胞的检测方法 |
| US20260108629A1 (en) * | 2024-08-14 | 2026-04-23 | Kite Pharma, Inc. | Vectors for production of therapeutic constructs |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO1998002558A2 (en) | 1996-07-17 | 1998-01-22 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
| WO2007075899A2 (en) | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| AU2009292996B2 (en) | 2008-09-22 | 2015-04-23 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters |
| WO2011069004A1 (en) * | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| EP2694640B1 (en) | 2011-04-08 | 2017-10-18 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| EP3569253A1 (en) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| AU2015330017A1 (en) | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| EP3234145B1 (en) | 2014-12-15 | 2019-06-05 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| CA2974998C (en) | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| HUE057285T2 (hu) * | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| TWI700298B (zh) * | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向b細胞成熟抗原之嵌合型抗原受體類 |
| WO2016168612A1 (en) | 2015-04-15 | 2016-10-20 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| WO2018161064A1 (en) | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| WO2019055946A1 (en) | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF |
| CN118546961A (zh) * | 2016-08-26 | 2024-08-27 | 贝勒医学院 | 用于细胞治疗的组成型活性细胞因子受体 |
| US11654158B2 (en) | 2016-11-17 | 2023-05-23 | 2Seventy Bio, Inc. | TGFBeta signal convertor |
| WO2018104473A1 (en) | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| GB201702617D0 (en) | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| SG11201908929VA (en) * | 2017-03-31 | 2019-10-30 | Univ Leland Stanford Junior | Synthekine compositions and methods of use |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| AU2019227979B2 (en) * | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| CN112533942A (zh) * | 2018-06-01 | 2021-03-19 | 华盛顿大学 | 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 |
| CN112368298A (zh) | 2018-06-22 | 2021-02-12 | 凯德药业股份有限公司 | 嵌合跨膜蛋白及其用途 |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| IL328846A (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases |
| IL285941B1 (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
-
2021
- 2021-02-24 PE PE2022001799A patent/PE20221757A1/es unknown
- 2021-02-24 AU AU2021227191A patent/AU2021227191A1/en active Pending
- 2021-02-24 CA CA3167065A patent/CA3167065A1/en active Pending
- 2021-02-24 MX MX2022010340A patent/MX2022010340A/es unknown
- 2021-02-24 IL IL295470A patent/IL295470A/en unknown
- 2021-02-24 KR KR1020227030983A patent/KR20220145846A/ko active Pending
- 2021-02-24 JP JP2022550184A patent/JP2023514407A/ja active Pending
- 2021-02-24 CN CN202180016621.7A patent/CN115175929A/zh active Pending
- 2021-02-24 BR BR112022016657A patent/BR112022016657A2/pt not_active IP Right Cessation
- 2021-02-24 WO PCT/US2021/019362 patent/WO2021173630A1/en not_active Ceased
- 2021-02-24 US US17/183,689 patent/US12036243B2/en active Active
- 2021-02-24 TW TW110106494A patent/TWI894211B/zh active
- 2021-02-24 PH PH1/2022/552033A patent/PH12022552033A1/en unknown
- 2021-02-24 EP EP21713206.7A patent/EP4110805A1/en active Pending
-
2022
- 2022-08-19 CO CONC2022/0011684A patent/CO2022011684A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023514407A (ja) | 2023-04-05 |
| PH12022552033A1 (en) | 2023-11-20 |
| AU2021227191A1 (en) | 2022-08-25 |
| IL295470A (en) | 2022-10-01 |
| WO2021173630A1 (en) | 2021-09-02 |
| CN115175929A (zh) | 2022-10-11 |
| PE20221757A1 (es) | 2022-11-11 |
| KR20220145846A (ko) | 2022-10-31 |
| US20210260118A1 (en) | 2021-08-26 |
| TW202146439A (zh) | 2021-12-16 |
| EP4110805A1 (en) | 2023-01-04 |
| MX2022010340A (es) | 2022-09-19 |
| CA3167065A1 (en) | 2021-09-02 |
| TWI894211B (zh) | 2025-08-21 |
| BR112022016657A2 (pt) | 2022-12-20 |
| US12036243B2 (en) | 2024-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221757A1 (es) | Celulas t con car de bcma con actividades mejoradas | |
| English et al. | Mesenchymal stromal cells: facilitators of successful transplantation? | |
| Burnham et al. | Mesenchymal stromal cells in hematopoietic cell transplantation | |
| CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
| PE20211902A1 (es) | Receptores de citocinas quimericos constitutivamente activos | |
| Auletta et al. | The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis | |
| MX2018006789A (es) | Receptores quimericos modificados y composiciones y metodos relacionados. | |
| MX2019001185A (es) | Polipeptidos inmunomoduladores y composiciones y metodos relacionados. | |
| CL2018003769A1 (es) | Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado. | |
| MX2017015239A (es) | Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas. | |
| KR20210149251A (ko) | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 | |
| CO2017007003A2 (es) | Formulaciones de sunitinib y métodos para uso de las mismas en el tratamiento de trastornos oculares | |
| CO2020006443A2 (es) | Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas | |
| MX2017005106A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| MX2019014761A (es) | Manejo de toxicidad para actividad antitumoral de cars. | |
| EP4414033A3 (en) | Treatment involving car-engineered t cells and cytokines | |
| MX2023008809A (es) | ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS. | |
| ECSP20082338A (es) | Receptores del factor de crecimiento quimérico | |
| Salerno et al. | Myocardial regeneration protocols towards the routine clinical scenario: An unseemly path from bench to bedside | |
| Liu et al. | Enhancing cytokine-induced killer cell therapy of multiple myeloma | |
| PE20140871A1 (es) | COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA | |
| AR116451A1 (es) | Administración oral de análogos del péptido glp-1 | |
| Broglie et al. | Yin and Yang of mesenchymal stem cells and aplastic anemia | |
| Li et al. | The role of γδ T cells in flavivirus infections: insights into immune defense and therapeutic opportunities | |
| MX2021002519A (es) | Antigenos derivados de retrovirus endogeno humano tipo k (herv-k) como antigenos tumorales compartidos para vacuna anti-cancerigena. |